PR Newswire · May 2026
The company said U.S. Patent No. 12,622,885 extends protection for a deuterated short-chain fatty acid class and supports NCE exclusivity through 2044.
Regulating the immune system to block cancer & autoimmune diseases
Company research
Public company, workplace, funding, and market signals
Overview
Clinical-stage biotechnology company developing oral deuterated short-chain fatty acid therapeutics that modulate the gut-immune axis, with SFA-002 as its lead candidate in psoriasis.
Primary product
SFA-002, an oral deuterated short-chain fatty acid therapeutic for psoriasis and other inflammatory/autoimmune diseases.
Founded
2016
Headquarters
Jenkintown, Pennsylvania, United States
Team size
1-10 employees
Industry
Biotechnology
Sub-industry
Clinical-stage biopharmaceuticals
Offices
610 Old York Road, Suite 400, Jenkintown, PA 19046
Open Positions
0 jobs at SFA Therapeutics
No open positions
Check back later for new openings